公开(公告)号：US10155767B2

公开(公告)日：2018-12-18

申请号：US15672987

申请日：2017-08-09

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Tae Bo Sim ,  Han Na Cho ,  Eun Hye Ju ,  Woo Young Hur ,  Ho Jong Yoon ,  Chi Man Song

IPC: C07D487/04

Abstract: The present invention provides a therapeutic agent of acute myeloid leukemia containing a 1,3,7-trisubstituted 3,4-dihydropyrimido[4,5-d]pyrimidine-2(1H)-one compound as an active ingredient, which has proliferation inhibitory activity for a human acute myeloid leukemia cell line OCI-AML3 having a NRAS mutant gene while having low inhibitory activity for wild type NRAS and has activity of inhibiting GCK and ACK1 protein kinases at the same time.

公开(公告)号：US10059717B2

公开(公告)日：2018-08-28

申请号：US15674023

申请日：2017-08-10

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： Tae Bo Sim ,  Woo Young Hur ,  Ho Jong Yoon ,  Chi Man Song ,  Eun Hye Ju ,  Han na Cho ,  Hwan Geun Choi

IPC: C07D487/04 ,  C07D403/14 ,  C07D401/14 ,  A61K31/4985 ,  A61P35/00 ,  A61P35/02

CPC classification number: C07D487/04 ,  C07D401/14 ,  C07D403/14

Abstract: The present invention provides a pharmaceutical composition, as an effective ingredient, a urea compound having a protein kinase inhibitory activity and containing a 3,4-dihydropyrimido[4,5-d]pyrimidin-2(1H)-one skeleton, and a pharmaceutically acceptable salt thereof.